Iza-bren extended control of HR+ breast cancer after hormone therapy and chemo
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with HR+/HER2- breast cancer that had progressed after hormone therapy, CDK4/6 inhibitors and chemotherapy went a median 8.2 months…